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The kidneys utilize roughly 10% of the body’s oxygen supply to produce the energy 
required for accomplishing their primary function: the regulation of body fluid composition 
through secreting, filtering, and reabsorbing metabolites and nutrients. To ensure an 
adequate ATP supply, the kidneys are particularly enriched in mitochondria, having the 
second highest mitochondrial content and thus oxygen consumption of our body. The 
bulk of the ATP generated in the kidneys is consumed to move solutes toward (reabsorption) 
or from (secretion) the peritubular capillaries through the concerted action of an array of 
ATP-binding cassette (ABC) pumps and transporters. ABC pumps function upon direct 
ATP hydrolysis. Transporters are driven by the ion electrochemical gradients and the 
membrane potential generated by the asymmetric transport of ions across the plasma 
membrane mediated by the ATPase pumps. Some of these transporters, namely the 
polyspecific organic anion transporters (OATs), the organic anion transporting polypeptides 
(OATPs), and the organic cation transporters (OCTs) are highly expressed on the proximal 
tubular cell membranes and happen to also transport drugs whose levels in the proximal 
tubular cells can rapidly rise, thereby damaging the mitochondria and resulting in cell 
death and kidney injury. Drug-induced kidney injury (DIKI) is a growing public health 
concern and a major cause of drug attrition in drug development and post-marketing 
approval. As part of the article collection “Mitochondria in Renal Health and Disease,” 
here, we provide a critical overview of the main molecular mechanisms underlying the 
mitochondrial damage caused by drugs inducing nephrotoxicity.
Keywords: antibiotic, anticancer, antiviral, drug-induced kidney injury, mitochondria, oxidative stress, 
proximal tubular cells
INTRODUCTION
Kidney Disease: Improving Global Outcomes (KDIGO) guidelines define acute kidney injury 
in patients with normal renal function (serum creatinine of 1.3–1.5  mg/dl) as: (i) a serum 
creatinine increases by 0.3  mg/dl or more within 48  h, (ii) a serum creatinine increases by 
50% or more from the baseline within the previous 7  days, and/or (iii) a urine volume is 
lower than 0.5  ml/kg/h for 6  h (Palevsky et  al., 2013). It has been estimated that 14–26% of 
all acute kidney injury cases are induced by drugs. Drug-induced kidney injury (DIKI) not 
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only represents a concerning public health issue but also 
substantially contributes to the rate of drug attrition in drug 
development and post-marketing approval (Mehta et  al., 2004; 
Uchino et  al., 2005; van der Meer et  al., 2010; Moffett and 
Goldstein, 2011; Hoste et  al., 2015). The incidence of DIKI 
seems to rise when we  consider new prescription drugs, likely 
because (i) some adverse drug reactions can only be  observed 
in large, genetically heterogeneous populations, only reachable 
several years upon marketing authorization, (ii) recognition of 
cases of DIKI is particularly challenging for medications not 
previously associated with kidney damage, because there is no 
consensus on the definition of DIKI, and (iii) some regulatory 
agencies have nearly halved the approval review times in the 
last 20  years, even in the absence of significant advantages for 
patients in comparison to existing medications (Olson, 2004; 
van der Meer et  al., 2010; Awdishu and Mehta, 2017).
The functional unit of the kidney is the nephron, which is 
composed of a glomerulus and a tubule. The glomerulus filters 
the blood, retaining cells and large proteins, producing an 
ultrafiltrate mainly made of small molecules, from nutrients to 
ions. The ultrafiltrate enters the tubule, in which highly specialized 
cells at various segments (proximal tubule, Henle’s loop, and 
distal tubule) contribute to modify the nascent urine by removing 
substances from the tubular fluid (reabsorption) or adding 
substances to the tubular fluid (secretion). For a long time, the 
recognition of the primary site of the renal damage induced by 
drugs has been complicated because only cases associated with 
a change in serum creatinine, which is a sign of extended tissue 
damage to the point of renal dysfunction, were recognized. With 
the introduction in preclinical and clinical development of a 
panel of segment-specific markers such as neutrophil gelatinase-
associated lipocalin (Ngal; Mishra et al., 2003) and urinary kidney 
injury molecule-1 (Kim-1; Ichimura et al., 1998; Han et al., 2002), 
thereby more explicitly addressing the etiology of the renal insult 
and identifying the injury before the serum creatinine elevates, 
it could be  established that the majority of the DIKI cases have 
a tubular etiology with primary glomerular injury being relatively 
uncommon (Mehta et  al., 2015). DIKI can be  idiosyncratic or 
intrinsic. Idiosyncratic DIKI is unpredictable and it often stems 
from a T cell response against the drug triggered by haptens 
presented by the human leukocyte antigen (HLA) molecules to 
the T cells (e.g., abacavir). Intrinsic DIKI is the result of a 
dose-dependent toxic effect of a drug and/or the metabolites 
thereof, often at the expense of mitochondria, which is followed 
by cell death and renal dysfunction (Mehta et  al., 2015).
Tubular cells are highly enriched in mitochondria to meet 
the high ATP demand to sustain the activity of the ATPase 
pumps and the transmembrane electrochemical gradients that 
drive the secretion and reabsorption of solutes (Soltoff, 1986). 
Mitochondrial ATP production is strictly oxygen-dependent as 
the oxidation reaction terminates with the reduction of an oxygen 
molecule to a water molecule in the final step of the mitochondrial 
electron transfer. Cytosolic ATP production is instead oxygen-
independent and it is exclusively derived from the oxidation of 
carbohydrates that enter the anaerobic glycolytic pathway. Due 
to the decreasing corticomedullary oxygen gradient, energy 
metabolism is quite heterogeneous throughout the tubule. 
The loop of Henle, which lies in the medullary tract, relies 
primarily on anaerobic glycolysis, whereas the proximal and 
distal tubular cells, which resides in the cortex, are enriched in 
mitochondria and produce ATP primarily from the β-oxidation 
of fatty acids in the mitochondrial matrix (Clark and Parikh, 
2020). Besides being the power plant of the proximal and distal 
tubular cells, mitochondria are also the hub of reactive oxygen 
species (ROS) production, which are harmless at low 
concentrations, but toxic to the mitochondria and the cell at 
high concentrations (Soltoff, 1986). The proximal segment of 
the tubule, which is the site of the secretion and the reabsorption 
of roughly 80% of the glomerular filtrate, is the most enriched 
in mitochondria (Soltoff, 1986). Another distinctive feature of 
the proximal tubular cells is the relatively high expression level 
of a series of polyspecific solute transporters, which can 
be occasionally hijacked to transport drugs from the peritubular 
blood into the urine or vice versa (Table  1; Fisel et  al., 2014). 
Transport proteins participating in tubular drug secretion and 
reabsorption are solute carriers (SLCs) and ATP binding cassette 
(ABC) pumps. The SLCs include organic anion transporters 
(OATs), organic cation transporters (OCTs), organic anion 
transporting polypeptides (OATPs), multidrug and toxic compound 
extrusion (MATE) proteins, and a variety of amino acids and 
vitamin transporters, such as the folate carriers reduced folate 
carrier (RFC) and the proton-coupled folate transporter (PCFT). 
These transporters are passive or secondary active transporters 
that facilitate the movement of substrates toward or against their 
electrochemical gradient (Verrey et  al., 2009; Zhao et  al., 2011; 
Hagenbuch and Stieger, 2013; Koepsell, 2013; Motohashi and 
Inui, 2013; Samodelov et  al., 2019). The ABC pumps are active 
transporters with bifunctional features: ATP hydrolysis and 
transport of the substrate. In the kidneys, the multidrug resistance 
proteins (MRPs) 2 and 4 and the breast cancer resistance protein 
(BCRP) appear to be  particularly relevant in the elimination of 
drugs (Leier et  al., 2000; Smeets et  al., 2004; Huls et  al., 2008).
The high expression level of these polyspecific transporters 
on the membranes of proximal tubular cells and their unique 
mitochondrial enrichment set the conditions for the “perfect 
storm,” resulting in exposure of mitochondria to high concentration 
of drugs, massive ATP depletion, intolerable oxidative stress, 
and proximal tubular cell death. The resulting kidney injury 
usually manifests as Fanconi’s syndrome, a general malabsorption 
of electrolytes and substances due to proximal tubule 
malfunctioning that can progress to renal insufficiency (Heidari, 
2019). As part of the article collection “Mitochondria in Renal 
Health and Disease,” this article provides an overview of the 
molecular mechanisms underlying drug-induced mitochondrial 
damage in DIKI. Sources for this review were obtained through 
extensive literature searches of publications browsing PubMed. 
Only papers published in the English language were considered.
MITOCHONDRIAL MEMBRANES
The mitochondrion is made of two membranes, known as the 
outer mitochondrial membrane and the inner mitochondrial 
membrane. The outer membrane is smooth and relatively 
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permeable to solutes smaller than 5  kDa. It has a low protein 
density and is considered important for the physical and 
signaling interaction between the mitochondrion and the other 
subcellular compartments. The inner mitochondrial membrane 
is relatively impermeable to solutes and has a high protein:lipid 
ratio allowed by its deeply convoluted shape (Giacomello et al., 
2020). The other distinctive feature of the inner membrane is 
the presence of cardiolipin, a lipid that is also found in bacterial 
membranes. Cardiolipin appears to be  essential for the 
mitochondrial respiration and pathological changes in cardiolipin 
amount or species composition have been shown to alter 
mitochondrial respiration, boosting the production of reactive 
oxygen species (Horvath and Daum, 2013; Dudek, 2017).
Experiments in which the polymyxin-resistant Acholeplasma 
laidlawii B bacteria, lacking the cell wall, were fused with vesicles 
loaded with different lipid species, revealed that cardiolipin and 
phosphatidylglycerol might represent the polymyxin receptor 
molecules in the prokaryotic membranes (Teuber and Bader, 
1976). Polymyxins are cyclic heptapeptide with an acylated 
tripeptide side chain, which disrupts the cell membrane integrity 
of the Gram-negative bacteria (Deris et  al., 2014; Yu et  al., 
2015). Polymyxins are reabsorbed at the level of the proximal 
tubule by endocytosis and facilitated diffusion. The endocytic 
uptake seems to involve the glycoprotein megalin (Suzuki et al., 
2013). In contrast, the human peptide transporter 2 (PEPT2) 
and the carnitine/organic cation transporter novel 2 (OCTN2), 
both highly expressed on the brush border membrane of proximal 
tubular cells, have been shown to facilitate the transport of 
polymyxins in overexpressing in vitro systems (Horvath and 
Daum, 2013; Lu et  al., 2016; Visentin et  al., 2017). Though 
destabilization of the plasma membrane is considered the primary 
mechanism of polymyxin toxicity, there are growing evidence 
that polymyxins induce also mitochondrial damage. The target 
of polymyxins in mitochondria is not known; however, it might 
be speculated that the interaction with cardiolipin might trigger 
mitochondrial membrane depolarization and apoptosis observed 
in proximal tubular cells (Dai et  al., 2013, 2014).
Amphotericin B is an antifungal agent widely administered 
against invasive fungal infections; however, its clinical application 
is limited by the frequent onset of nephrotoxicity (Heidari, 2019). 
The mechanism by which amphotericin B accumulates in the 
proximal tubular cells is unclear. In vitro experiments showed 
that amphotericin B is a strong inhibitor of the human OCT2 
but not its substrate (Trejtnar et  al., 2014). Experiments in 
Aspergillus fumigatus showed that amphotericin B binds to the 
membrane lipids of the mitochondrial membranes, inducing loss 
of integrity, ROS production, oxidative stress, and lipid peroxidation 
(Shekhova et al., 2017). Notably, amphotericin B-induced oxidative 
stress can be  markedly reduced by inhibiting the complex I  of 
the electron transport chain, the major site of ROS formation 
(Mesa-Arango et  al., 2014; Shekhova et  al., 2017).
MITOCHONDRIAL DNA REPLICATION, 
TRANSCRIPTION, AND TRANSLATION
Mitochondrial DNA is double stranded like the nuclear DNA, 
but circular instead of linear. The mitochondrial genome encodes 
exclusively for two ribosomal RNAs (rRNAs), 22 transfer RNAs 
(tRNAs), and the messenger RNA (mRNA) of 13 protein 
subunits that are assembled with nuclear-encoded proteins to 
form the four enzymatic complexes constituting the mitochondrial 
TABLE 1 | List of drugs associated with acute kidney injury and mitochondrial damage.
Class Name Transporter Target References
Antibiotic
Colistin Megalin, PEPT2, and OCTN2
Mitochondrial membrane 
AMID*
(Teuber and Bader, 1976; Suzuki et al., 2013; Deris et al., 
2014; Lu et al., 2016; Visentin et al., 2017)
Doxycycline OATs Mitochondrial ribosome
(Clark-Walker and Linnane, 1966; Babu et al., 2002; 
Houtkooper et al. 2013; Moullan et al., 2015)
Gentamicin Megalin and OCT2
Mitochondrial ribosome 
Complex II
(Prezant et al., 1993; Moestrup et al., 1995; Qian and Guan, 
2009; Gai et al., 2016; O’reilly et al., 2019)
Vancomycin OCTs Complex I
(Sokol, 1991; Arimura et al., 2012; Fujiwara et al., 2012; 
Sakamoto et al., 2017)
Anticancer
Cisplatin OCTs Mitochondrial DNA VDAC
(Yang et al., 2006; Garrido et al., 2008; Filipski et al., 2009; 
Ciarimboli et al., 2010)
Gemcitabine CNTs and ENTs DNA polimerase γ (Mackey et al., 1998; Fowler et al., 2008)
Ifosfamide OCT2 Complex I
(Nissim et al., 2006; Knouzy et al., 2010; Ciarimboli et al., 
2011)
Methotrexate
FRα, RFC, PCFT, OATs, and OATPs
Mitochondrial TS
(Hoar and Dimnik, 1985; Badagnani et al., 2006; Zhao et al., 
2011; Visentin et al., 2012)
Nitrosourea derivatives OCTs Mitochondrial DNA
(Wunderlich et al., 1970; Pettepher et al., 1991; Chen et al., 
2001).




CNTs and ENTs DNA polimerase γ (Birkus et al., 2002; Pinti et al., 2006)
Others
Aristolochic acid OATs ANT (Qi et al., 2007; Bakhiya et al., 2009; Xue et al., 2011)
Carboxy-atractyloside Unknown ANT (Klingenberg, 2008)
AMID, apoptosis-inducing factor-homologous mitochondrion associated inducer of death; ANT, adenine nucleotide translocase; CNT, concentrative nucleoside transporter; ENT, 
equilibrative nucleoside transporter; FR, folate receptor; OAT, organic anion transporter; OATPs, organic anion transporting polypeptide; OCT, organic cation transporter; PCFT, 
proton-coupled folate transporter; RFC, reduced folate carrier; TS, thymidylate synthase; VDAC, voltage-dependent anion channel. *Based on phylogenetic analysis.
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electron transport chain. Mitochondrial genes are transcribed 
in a polycistronic manner, whereas nuclear genes are usually 
transcribed as individual mRNAs. Mitoribosomes, mitochondrial 
tRNAs, and mRNAs form the translation apparatus; however, 
the translation process is completely dependent on various 
nuclear-encoded regulatory proteins (D’souza and Minczuk, 
2018). Inhibition of mitochondrial DNA replication and/or 
protein synthesis, described for multiple classes of drugs 
associated with acute kidney injury (Table  1), results in the 
reduction of the steady-state level of mitochondrion-encoded 
proteins, a phenomenon known as mitonuclear protein imbalance, 
which causes reduced cellular respiration and altered 
mitochondria dynamics (Houtkooper et  al., 2013).
DNA Replication
The replication of the mitochondrial genome relies on the 
expression and activity of the DNA polymerase γ, which is 
encoded by the nuclear gene POLG. The DNA polymerase γ 
has two domains: a catalytic one with polymerase activity and 
an exonuclease one that corrects misincorporations during DNA 
replication (Kaguni, 2004). Direct inhibition of the DNA 
polymerase γ activity is considered the mechanism underlying 
acyclic nucleotide analogue-induced acute kidney injury 
(Leowattana, 2019). Acyclic nucleotide analogues are widely used 
to prevent the replication of viruses, such as hepatitis B virus 
(e.g., lamivudine), hepatitis C virus (e.g., ribavirin), herpes simplex 
(e.g., acyclovir), and human immunodeficiency virus (HIV; e.g., 
zidovudine). The uptake and accumulation of acyclic nucleotide 
analogues are mainly mediated by concentrative nucleoside 
transporters (CNTs) and equilibrative nucleoside transporters 
(ENTs) transporters, which are expressed throughout the body 
and at relatively high levels in the proximal tubular cells. Once 
inside the cell, acyclic nucleotide analogues must be phosphorylated 
through three consecutive phosphorylation steps to be  able to 
interact with the viral DNA polymerase. Of crucial importance 
is the first phosphorylation step, which is the only one ensured 
by the viral machinery, whereas the other two reactions are 
mediated by the host kinases. In the triphosphate form, the 
drugs interact, as competitive inhibitors or alternate substrates, 
with the dNTPs, and if they are incorporated into the DNA 
strand, they terminate its extension (De Clercq, 2003). Such 
interaction is not specific for the viral polymerase. Experiments 
in different mammalian cells, including human primary renal 
proximal tubule epithelial cells, with zalcitabine, didanosine, 
stavudine, and zidovudine suggest that acyclic nucleotide analogues 
directly interfere with mitochondrial DNA replication catalyzed 
by the DNA polymerase γ. The ratio between mitochondrial 
DNA and chromosomal DNA, and the expression of mitochondrial 
proteins is markedly reduced by the exposure to acyclic nucleotide 
analogues, leading to mitonuclear protein imbalance. In line 
with a reduced oxygen-dependent ATP production, the treatment 
with acyclic nucleotide analogues has been shown to induce 
the production of lactate in vitro, likely as a result of a glycolytic 
boost (Birkus et  al., 2002; Pinti et  al., 2006). The inhibition of 
the DNA polymerase γ by acyclic nucleotide analogues can occur 
through four different mechanisms: (i) replication is halted, (ii) 
competitive inhibition with natural nucleotides, (iii) increased 
error rate in the mitochondrial DNA replication inhibiting the 
exonucleolytic proofreading function of polymerase γ, and (iv) 
decreased exonuclease activity (Lewis et  al., 2003). It has been 
found that the extension of the nucleotide moiety through a 
stable phosphate-carbon bond (phosphonate) results in a markedly 
reduced mitochondrial and renal toxicity (Verhelst et  al., 2002; 
Izzedine et  al., 2005; Fernandez-Fernandez et  al., 2011). This 
chemical modification leads to a profound alteration of the 
cellular pharmacology and toxicology of acyclic nucleotides: (i) 
due to their negative charge, the uptake of acyclic nucleotide 
phosphonates in the kidney cortex is primarily mediated by the 
organic anion transporter 1 (OAT1) and not by CTNs and ENTs, 
(ii) acyclic nucleotide phosphonates are direct substrates of the 
cellular kinases, bypassing the virus-dependent phosphorylation, 
being effective in the treatment of kinase deficient viruses, (iii) 
in contrast to the phosphate group (attached through a P-O-C 
bond), the phosphonate group cannot be  cleaved off by cellular 
hydrolases, facilitating the cellular retention of the drug (Cihlar 
et  al., 1999; Ho et  al., 2000; Uwai et  al., 2007), and (iv) acyclic 
nucleotide phosphonates, unlike acyclic nucleotide analogues, are 
weak inhibitors of the DNA polymerase γ. Though swollen and 
dysmorphic mitochondria and depletion of mitochondrial DNA 
have been described in patients who experienced nephrotoxicity 
upon treatment with acyclic nucleotide phosphonates (Tanji et al., 
2001; Saumoy et  al., 2004), in vitro experiments demonstrated 
that acyclic nucleotide phosphonates do not interfere with 
mitochondrial DNA synthesis and do not induce mitochondrial 
toxicity and renal toxicity in mammalian cells (Birkus et  al., 
2002). Likely, the mitochondrial toxicity observed in those patients 
was not related to the exposure to the acyclic nucleotide 
phosphonates but rather to the co-treatment with acyclic nucleotide 
analogues and hydroxyurea, both highly nephrotoxic (Tanji et al., 
2001; Saumoy et  al., 2004; Singh and Xu, 2016). The inhibition 
of the DNA polymerase γ has been also reported for gemcitabine, 
a pyrimidine nucleoside analog employed in the treatment of 
a number of cancers. Though peripheral neuropathy and 
hematological dysfunction are the most common side effects of 
this drug, several cases of kidney injury have been reported 
(Heidari, 2019). Like acyclic nucleotide analogues, gemcitabine 
is taken up by CNTs and ENTs (Mackey et  al., 1998) and 
accumulates in the cytoplasm and in the mitochondria, inducing 
swelling of the mitochondria and function alteration (Heidari, 
2019). Pre-steady state kinetic experiments showed that gemcitabine 
directly inhibits the activity of the human DNA polymerase γ 
(Fowler et  al., 2008).
The inhibition of mitochondrial DNA replication can also 
occur as a consequence of DNA covalent modifications, which 
are a probable mechanism underlying alkylating agent-induced 
mitochondrial damage such as platinum and nitrosourea 
derivatives. Cisplatin, used as first-line treatment of various 
types of cancer, is a first-generation platinum-based drug 
and the most nephrotoxic among the platinum derivatives 
(Miller et  al., 2010). The uptake of cisplatin in the proximal 
tubular cells is primarily mediated by the OCT2, which is 
highly expressed on the basolateral membrane, thus it is 
likely to mediate the entry step of cisplatin tubular secretion. 
After treatment with cisplatin, the double knockout mouse 
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Oct1/2−/− displayed a milder nephrotoxicity as compared with 
the wild-type animal. Moreover, patients carrying the 
nonsynonymous single-nucleotide polymorphism (SNP) in 
the OCT2 gene SLC22A2 (rs316019), causing a reduction in 
the transport activity, have been associated with a reduced 
risk of cisplatin-induced nephrotoxicity (Filipski et  al., 2009; 
Ciarimboli et  al., 2010). There is a large body of evidence 
that the toxic effects of cisplatin are primarily the result of 
inter‐ and intra-strand covalent adduct formation between 
platinum complexes and DNA. Interestingly, dissociation-
enhanced lanthanide fluoroimmunoassay studies performed 
in Chinese hamster ovary (CHO) cells demonstrated that 
the rate of cisplatin-DNA adduct incorporation was much 
higher in mitochondrial DNA than in genomic DNA (Olivero 
et al., 1995), which leads to inhibition of the DNA amplification 
by polymerase chain reaction (PCR) and impairment of 
mitochondrial DNA stability and RNA synthesis (Garrido 
et  al., 2008). Using a panel of cancer cell lines, it has been 
observed that, unlike the complex I  inhibitor rotenone and 
the uncoupler carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP), which instantaneously alter cellular oxygen 
consumption, cisplatin inhibited mitochondrial respiration 
only after hours of exposure, a timeframe that is consistent 
with a mitonuclear protein imbalance-dependent effect 
(Gerschenson et al., 2001; Alborzinia et al., 2011). Noteworthy, 
it has been shown that there is a positive correlation between 
the cellular density of mitochondria and cisplatin-induced 
toxicity (Qian et  al., 2005), an observation that provides 
another explanation for the sensitivity of proximal tubular 
cells to cisplatin. Damage at the level of the mitochondrial 
DNA is likely to be  also the primary mechanism of 
nephrotoxicity induced by antineoplastic nitrosourea derivatives 
(Perry and Weiss, 1982; Narins et al., 1990). After incubation 
of isolated mitochondria or cell nuclei with radiolabeled 
methyl-N-nitrosourea, the incorporation into the mitochondrial 
DNA was 3–7 times that of the nuclear DNA (Wunderlich 
et  al., 1970). Likewise, after intraperitoneal injection in rats 
of nitrosourea derivatives, the extent of the DNA damage 
was much higher in the mitochondria than in the nuclei 
(Wunderlich et al., 1970; Pettepher et al., 1991). The mechanism 
of accumulation of nitrosourea derivatives in the proximal 
tubular cells is not fully understood, though association 
studies have indicated that the expression of organic cation 
transporters correlated with the cytotoxic effect of nitrosourea 
derivatives in vitro (Noe et  al., 1996; Chen et  al., 2001). 
The mitochondrial selectivity of alkylating agents might 
be  explained by a higher accumulation of these drugs in 
the mitochondria as compared with the nuclei and the lack 
of histones, which could make the mitochondrial DNA more 
vulnerable than the genomic DNA to the attack of these 
alkylating agents (Wunderlich et  al., 1970).
Mitochondrial mutations have been observed upon treatment 
with methotrexate in vitro. Methotrexate belongs to the antifolates, 
the first class of antimetabolites to enter the clinics in the 
1950s. Methotrexate inhibits the dihydrofolate reductase, rapidly 
depleting the cells of tetrahydrofolate derivatives that are key 
cofactors for the synthesis of thymidylate and purines, the 
building blocks of DNA and RNA synthesis. The uptake of 
methotrexate in the proximal tubular cells is mediated by the 
glycosylphosphatidylinositol (GPI) anchored high-affinity folate 
receptor α (FRα), by the specific folate transporters RFC and 
PCFT, and by OATs and OATPs (Badagnani et  al., 2006; Zhao 
et  al., 2011; Visentin et  al., 2012; Samodelov et  al., 2019). The 
etiology of methotrexate-induced renal dysfunction is believed 
to be  primarily the consequence of the precipitation of the 
drug in the renal tubules because of its poor solubility at 
acidic pH (Jacobs et  al., 1976; Smeland et  al., 1996). Yet, it 
has been proposed that methotrexate can exert its toxic effect 
by accumulating in the mitochondrial matrix via the 
mitochondrial folate transporter (MFT; Titus and Moran, 2000). 
In vitro experiments indicated that the mutagenesis induced 
by methotrexate in non-proliferating cells seems to occur solely 
at the level of the mitochondrial DNA, sparing the nuclear 
genome. Because similar results were obtained with 
5-fluorodeoxyuridine, the deoxyribonucleoside derivative of 
5-fluorouracil, another thymidylate synthase inhibitor widely 
used in cancer treatment, it is likely that the alteration in the 
mitochondrial thymidylate pool underlies methotrexate-induced 
mitochondrial DNA mutations (Hoar and Dimnik, 1985). 
Notably, though 5-fluorouracil has been shown to cause 
nephrotoxicity in rats, it is not nephrotoxic in patients at 
clinically relevant doses (Rashid et  al., 2014). The basis for 
the mitochondrial DNA selectivity of these drugs may be  due 
to the difference in the origin of the thymidylate pool that 
are incorporated in the mitochondrial DNA and in the nuclear 
DNA. The de novo synthesis of thymidine triphosphate relies 
on the thymidylate synthase enzyme, which catalyzes the 
methylation of deoxyuridine monophosphate to thymidine 
monophosphate. Alternatively, thymidine monophosphate can 
also synthesize from a salvage pathway catalyzed by the cytosolic 
thymidine kinase 1. The expression level of thymidylate synthase 
and thymidine kinase 1 is cell cycle-dependent; thus, it is 
found in trivial amount in quiescent cells (Ke and Chang, 
2004; Le Francois et al., 2007). Mitochondrial thymidine kinase 
2 plays a pivotal role in thymidine triphosphate synthesis for 
mitochondrial DNA replication, which occurs also in 
non-dividing cells. Because of their differential expression in 
quiescent cells, such as proximal tubular cells, the inhibition 
of mitochondrial thymidine kinase 2, rather than thymidylate 
synthase and thymidine kinase 1, is likely to contribute to 
methotrexate-induced renal toxicity.
Protein Synthesis
Eukaryotic cells arose from the endosymbiosis of a 
α-proteobacterium with a host cell with no mitochondria. 
Mitochondria still harbor remnants of the ancestral bacterial 
genome and have retained their own transcriptional and 
translational machinery (Gray et  al., 1999). Thus, it is not 
surprising that mitochondrial protein synthesis is often the 
target of antibiotics initially developed to inhibit bacterial 
protein synthesis.
Aminoglycosides are potent inhibitors of the bacterial protein 
synthesis, whose clinical use is limited by the rapid onset of 
nephrotoxicity (and ototoxicity). The tropism of aminoglycosides 
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for the kidneys (and the inner ear) is likely due to the preferential 
accumulation of this class of antibiotics in these tissues mediated 
by the low-density lipoprotein receptor-related protein megalin 
(Moestrup et  al., 1995) and the OCT2 (Gai et  al., 2016), both 
highly expressed in these tissues. The relevance of OCT2  in 
aminoglycoside-induced kidney injury is supported by the 
clinical observation that male and obese individuals, both 
characterized by a high expression level of OCT2, carry a 
higher risk than women or lean individuals of developing 
toxicity during aminoglycoside therapy (Corcoran et  al., 1988; 
Urakami et  al., 2000). Aminoglycosides interfere with bacterial 
protein synthesis by binding to the internal loop in helix44 
of the 16S ribosomal RNA in the 30S subunit of bacterial 
ribosomes and to the terminal hairpin of helix69 of the bacterial 
large ribosomal subunit (Borovinskaya et al., 2007), which plays 
a critical role in ribosomal recycling and translocation (Woodcock 
et  al., 1991; Wang et  al., 2012). The aminoglycosides also cause 
a miscoding of mRNA codons, and, consequently, incorrect 
amino acids are incorporated into growing peptide chains 
producing faulty bacterial proteins (Davis, 1987). However, 
aminoglycosides also bind with lower affinity to mitochondrial 
ribosomes, exerting a toxic effect also on host cells in the 
event of high intracellular drug concentrations. By studying 
the mitochondrial 12S rRNA A1555G mutation, a well-known 
susceptibility factor in aminoglycoside-induced hearing loss, it 
was observed that the G1555 variant has higher affinity 
for aminoglycosides, directly demonstrating that human 
mitochondrial 12S rRNA is a target of aminoglycosides (Prezant 
et al., 1993; Qian and Guan, 2009). Moreover, the aminoglycosides 
exhibit similar binding affinities to the mitochondrial helix69. 
The interaction enhances the conformational stability of 
mitochondrial helix69 and increases the structural stability of 
the rRNA, hindering ribosomal recycling (Hong et  al., 2015).
Tetracycline antibiotics are used for the treatment of a broad 
range of microorganism infections, including those induced by 
Gram-positive and Gram-negative bacteria. Though they have 
been primarily associated with liver-induced steatosis, tetracyclines 
can also induce nephrotoxicity (Lew and French, 1966; Phillips 
et  al., 1974). In the 1960s, several case reports linked the onset 
of an acquired and usually reversible Fanconi’s syndrome with 
the use of tetracyclines. The authors ascribed the toxic effect 
to the degradation product epi-anhydrotetracycline, which induced 
proximal tubular necrosis in rats and dogs (Benitz and Diermeier, 
1964; Tapp et  al., 1965). Uptake of tetracyclines in the proximal 
tubular cells is likely mediated by the OAT1, OAT2, OAT3, 
and OAT4, which are highly expressed on the brush border 
and the basolateral membranes of the proximal tubular cells 
(Babu et  al., 2002). By exploiting their intrinsic fluorescence, 
it was demonstrated that tetracyclines rapidly accumulate in 
the mitochondria (Du Buy and Showacre, 1961). Like 
aminoglycosides, tetracyclines inhibit bacterial protein synthesis 
by binding to the ribosomal 30S subunit, preventing the association 
of aminoacyl-tRNA with the bacterial ribosome (Chopra and 
Roberts, 2001). Tetracyclines inhibit the translation of proteins 
encoded by the mitochondrial DNA, but not by the nuclear 
DNA, leading to mitonuclear protein imbalance (Clark-Walker 
and Linnane, 1966; Houtkooper et al., 2013; Moullan et al., 2015). 
Indeed, the gene expression profile of the human bladder cancer 
cell line RT112 exposed to doxycycline indicated a global repression 
of the mitochondrial protein synthesis and function (Moullan 
et  al., 2015). Also, mitochondria isolated from the liver of mice 
treated with doxycycline were characterized by decreased 
mitochondrial respiration and ATP content, and repression of 
several mitochondrial genes (Moullan et  al., 2015). The extensive 
experimental evidence on the impact of tetracyclines on mitochondria 
not only shed light on the molecular mechanisms of tetracycline-
induced toxicity but also raised awareness within the scientific 
community on the use of these antibiotics for inducible gene 
expression in the Tet-ON/Tet-OFF system. The mitochondrial 
dysregulation associated with the use of these antibiotics may 
be a relevant pitfall in the study of mitochondrial-related disorders 
(Chatzispyrou et al., 2015; Moullan et al., 2015; Luger et al., 2018).
ELECTRON TRANSPORT CHAIN
Reducing equivalents generated from the metabolism of glucose, 
lipids and amino acids flow into the tricarboxylic acid cycle 
and the electron transport chain to ultimately produce ATP. 
The tricarboxylic acid cycle is characterized by eight enzymatic 
steps, which generate flavin adenine dinucleotide (FADH2) 
and nicotinamide adenine dinucleotide (NADH) from FAD 
and NAD+. These reduction-oxidation reactions feeds the 
electron transport chain, a series of multi-subunit proteins, 
prosthetic groups, and cofactors embedded in the inner 
mitochondrial membrane. A second series of reduction-
oxidation reactions catalyzed by the electron transport chain 
generates the inward proton gradient required to drive the 
synthesis of ATP mediated by the F0F1-ATP synthase. Five 
complexes constitute the electron transport chain with complex 
V being F0F1-ATP synthase. Especially, complex I and complex 
II appear to be  the target of a number of widely prescribed 
drugs (Alberts et  al., 2002).
NADH:Ubiquinone 
Oxidoreductase – Complex I
Complex I  oxidizes NADH, transferring two electrons to 
ubiquinone (Coenzyme Q, CoQ), a lipophilic electron carrier, 
and four protons into the intermembrane space. Complex I, 
together with complex II, is the primary source of ROS 
production in the cell. The most common complex I  inhibitor 
is rotenone though 60 different families of compounds with 
inhibitory effect at the level of complex I  have been identified 
thus far (Lenaz et  al., 2006). Examples of complex I-related 
DIKI are the anticancer chemotherapeutic ifosfamide and the 
antibiotic vancomycin.
Ifosfamide is an alkylating agent used in anticancer 
chemotherapeutic protocols for treating several malignancies, 
including testicular cancer, soft tissue sarcoma, osteosarcoma, 
and bladder cancer. The treatment with ifosfamide but not 
with its structural isomer cyclophosphamide has been associated 
with tubular dysfunction. The uptake of ifosfamide in proximal 
tubular cells is mediated primarily by OCT2 and coadministration 
of cimetidine, another OCT2 substrate, completely prevented 
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ifosfamide-induced toxicity in isolated mouse proximal tubules. 
Notably OCT2 does not transport cyclophosphamide (Ciarimboli 
et  al., 2011). The mitochondria of the renal cortex from rats 
treated with ifosfamide showed a 50% decrease in State 3 
respiration with complex I  substrates but not with complex 
II substrates, suggesting that complex I inhibition might underlie 
ifosfamide-mitochondrial toxicity. Moreover, it has been shown 
that chloroacetaldehyde, an ifosfamide metabolite, inhibits 
complex I  in rat renal cortical slices as well (Nissim et  al., 
2006; Knouzy et  al., 2010). Co-injection with agmatine, a 
stimulator of fatty acid β-oxidation, sustained oxidative 
phosphorylation in the presence of ifosfamide. The authors 
suggested that agmatine might bypass the block of 
chloroacetaldehyde at the level of the complex I  by feeding 
the complex II. However, it is worth to mention that agmatine 
is also a substrate of OCT2, hence the co-administration of 
agmatine might as well reduce OCT2-mediated uptake of 
ifosfamide in proximal tubular cells (Nissim et al., 2006; Winter 
et al., 2011). In patients treated with carboplatin and ifosfamide, 
who developed Fanconi-like syndrome, decreased expression 
of the complex III and IV and deletions in mitochondrial 
DNA were observed (Di Cataldo et  al., 1999). However, this 
finding might be  the result of the interaction of carboplatin 
with mitochondrial and nuclear DNA rather than that of 
ifosfamide with complex I.
Vancomycin is an amphoteric glycopeptide antibiotic used 
to treat Gram-positive bacterial infections that do not respond 
to other antibiotics. Though not fully characterized, vancomycin 
selectively accumulates in the proximal tubular cells by active 
tubular secretion from the peritubular blood likely mediated 
by organic cation transporters (Sokol, 1991; Fujiwara et  al., 
2012). The only known biological target of vancomycin is the 
bacterial cell wall. Vancomycin inhibits the biosynthesis of 
bacterial cell wall peptidoglycan by binding C-terminal acyl-
D-alanyl-D-alanine (acyl-d-Ala-d-Ala)-containing residues in 
peptidoglycan precursors (Reynolds, 1989), a prokaryotic 
structure. Such selectivity is difficult to reconcile with any 
off-target effect in the proximal tubular cells, suggesting that, 
perhaps at very high intracellular concentrations, the vancomycin 
antibacterial effect might be pleiotropic and most probably less 
specific. Experiments with LLC-PK1 cells showed that vancomycin 
binds to and inhibit complex I activity, stimulating the production 
of superoxide, leading to peroxidation of the mitochondrial 
phospholipid cardiolipin and mitochondrial membrane 
depolarization followed by activation of the intrinsic apoptotic 
pathway. Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone 
(FCCP), a protonophore that dissipates the proton gradient of 
the mitochondrial membrane, thereby inhibiting superoxide 
production and reducing cardiolipin peroxidation, and ameliorates 
vancomycin mitochondrial toxicity, suggesting that the ROS 
generated upon complex I  inhibition promotes cardiolipin 
peroxidation followed by mitochondrial membrane depolarization 
and apoptosis (Orrenius, 2007; Arimura et  al., 2012; 
Hanske et  al., 2012; Sakamoto et  al., 2017).
There is evidence that polymyxins might inhibit bacterial 
cellular respiration not only by interacting with the mitochondrial 
membrane lipids but also by binding to the complex I 
(Tochikubo et  al., 1986; Mogi et  al., 2009). The prokaryotic 
respiratory chain consists of three complexes that move electrons 
and protons between large protein complexes (Kim and Kim, 
2004; Kerscher et  al., 2008). Complex I  consists of three inner 
membrane respiratory enzymes: the proton-translocating 
NADH-quinone (Q) oxidoreductase (NDH-1), the NADH-Q 
oxidoreductase (NDH-2), and the sodium-translocating NADH-Q 
oxidoreductase (Yagi et al., 1998). Polymyxins have been shown 
to inhibit the NDH-2 activity in a non-competitive manner 
(Deris et  al., 2014). Phylogenetic comparisons clustered the 
human protein apoptosis-inducing factor-homologous 
mitochondrion associated inducer of death, AMID (AIF-M2) 
with the prokaryotic NDH-2 family and not in the group 
containing the canonic AIF proteins, mitochondrial flavoproteins 
with oxidoreductase activity (Marshall et  al., 2005; 
Elguindy and Nakamaru-Ogiso, 2015; Marreiros et  al., 2016).
Succinate-Coenzyme Q 
Reductase – Complex II
Complex II is the succinate dehydrogenase, an enzyme also 
involved in the oxidation of succinate to fumarate as part of 
the tricarboxylic acid cycle. As part of the electron transport 
chain, succinate dehydrogenase, like complex I, transfers electrons 
from succinate to ubiquinone (Bezawork-Geleta et  al., 2017). 
Complex II-mediated ROS production is considered key in 
ischemia/reperfusion injury (Ralph et  al., 2011). It has been 
shown that the antibiotic gentamicin, the most commonly 
prescribed aminoglycoside, is not only an inhibitor of 
mitochondrial protein synthesis but can also directly interact 
with complex II. In cochlear sensory hair cells, gentamicin 
stimulates state 4 and inhibits state 3u respiratory rates by 
inhibiting complex II of the electron transport chain, thereby 
reducing the respiratory control ratio and collapsing the 
mitochondrial membrane potential as an uncoupler of the 
electron transport chain. As already known for other uncouplers, 
gentamicin reduced ROS production in isolated mitochondria 
(O’reilly et  al., 2019). By contrast, intact cells and animals 
treated with aminoglycosides overproduce ROS (Cuzzocrea 
et al., 2002; Kalghatgi et al., 2013), perhaps in a mitochondrion-
independent manner. In fact, it has been shown that gentamicin 
can also form ternary complexes with iron and lipid and 
catalyze ROS formation (Lesniak et  al., 2005).
MITOCHONDRIAL PERMEABILITY 
TRANSITION PORE
The permeability transition represents a sudden increase of 
the inner mitochondrial membrane permeability to solutes with 
a molecular weight lower than 1.5  kDa. Short-term openings 
of the permeability transition pore represent physiological 
adjustments to regulate Ca2+ and ROS homeostasis, providing 
mitochondria with a fast mechanism to release Ca2+ when this 
reaches a harmful concentration inside the mitochondrial matrix. 
Conversely, long-term opening of the pore is linked to 
mitochondrial dysfunction because its occurrence leads to 
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mitochondrial depolarization, cessation of ATP synthesis, Ca2+ 
release, pyridine nucleotide depletion, and inhibition of 
respiration. In vitro, long-term opening of the pore lead to 
matrix swelling, which, in turn, causes the mobilization of 
cytochrome c, the outer mitochondrial membrane rupture, and 
eventually the release of proapoptotic proteins such as cytochrome 
c. The precise molecular composition and identity of the 
mitochondrial permeability transition pore are still controversial. 
Candidate components of the pore are the adenine nucleotide 
translocase (ANT), the voltage dependent anion channel (VDAC), 
the phosphate carrier (PiC), and components of the ATP 
synthase (Bernardi and Di Lisa, 2015).
It has been suggested that taxane-induced and platinum-
induced mitochondrial injury might be associated to a direct 
interaction with the permeability transition pore. Though 
there is a large body of evidence that therapeutic and toxic 
effects of cisplatin on cells is primarily a consequence of 
inter-strand and intra-strand covalent adduct formation 
with nucleic acids, it has been shown that platinum can 
also crosslink with proteins. Experiments in intact cells 
suggest that cisplatin, perhaps conjugated to glutathione, 
accumulates in mitochondria, rapidly impairs the oxygen 
consumption, and induces oxidative stress (Dzamitika et al., 
2006; Garrido et  al., 2008). Depending on the source, 
oxidative stress not only can originate from mitochondria 
but also from other organelles, especially endoplasmic 
reticulum (ER) and peroxisomes (Kaludercic et  al., 2014). 
Co-localization experiments in Human Kidney-2 (HK-2) cells 
demonstrated that cisplatin-induced ROS is of mitochondrial 
origin (Choi et  al., 2015). It has been shown that cisplatin 
can form crosslinks with the VDAC, facilitating mitochondrial 
membrane permeabilization, release of cytochrome c, and 
apoptosis (Yang et  al., 2006). Short exposure to paclitaxel 
produces marked loss of renal tubules epithelial lining and 
damage of the brush border membranes with signs of both 
oncotic necrosis and apoptosis (Rabah, 2010). Paclitaxel induces 
an abrupt fall of the mitochondrial membrane potential and 
a loss of mitochondrial Ca2+. Because cyclosporin A, a 
de-sensitizer of the mitochondrial permeability transition pore, 
blocked paclitaxel-induced loss of mitochondrial Ca2+, the 
authors concluded that paclitaxel induced the opening of the 
mitochondrial permeability transition pore (Kidd et al., 2002).
The opening of the transition pore has also been associated 
with nephrotoxicity induced by some natural products very 
popular in traditional medicine. Xanthium strumarium, used 
in traditional Chinese medicine to treat nasal and sinus 
congestion, has been linked to several cases of poisoning with 
renal proximal tubular necrosis features which upon 
X. strumarium ingestion have been reported in the literature 
(Turgut et  al., 2005). The seeds of this plant are enriched in 
carboxyatractyloside, a well-characterized inhibitor of the ANT. 
The binding of carboxyatractyloside to the ANT triggers the 
opening of the mitochondrial transition pore (Obatomi et  al., 
1998; Klingenberg, 2008). In 1992, a high prevalence of kidney 
disease in female patients ingesting slimming pills raised 
attention to the nephrotoxicity of aristolochic acids. Ever since, 
aristolochic acids are considered a group of toxins that can 
cause end-stage renal failure associated with urothelial 
carcinomas (Han et al., 2019). Aristolochic acid is transported 
into the proximal tubular cells by the OATs (Bakhiya et  al., 
2009; Xue et  al., 2011). Studies in HK-2 cells showed that 
aristolochic acid exposure caused ATP depletion, mitochondrial 
membrane depolarization, cytochrome c release, and increase 
of caspase 3 activity. These toxic effects were attenuated by 
cyclosporin A, a known “desensitizer” of the opening of the 
pore (Bernardi, 1996). Experiments in isolated mitochondria 
showed that aristolochic acid inhibited the activity of the 
mitochondrial ANT (Qi et  al., 2007).
PROTECTIVE STRATEGIES
In principle, there are two approaches to protect the kidneys 
from drug toxicity. The first approach is reducing the intracellular 
accumulation of the drug by selectively inhibiting its uptake. 
A number of works have focused on the pharmacological 
inhibition of OCT2. It has been shown that the inhibition of 
OCT2 activity with cimetidine or agmatine, two OCT2 substrates, 
prevents nephrotoxicity induced by drugs that are OCT2 
substrates such as cisplatin and ifosfamide (Nissim et al., 2006; 
Ciarimboli et al., 2010, 2011). It remains unclear how metformin 
protects from gentamicin-induced kidney injury. Metformin, 
a well-known OCT2 substrate, prevents gentamicin-induced 
nephropathy in rats (Morales et al., 2010; Nasri, 2012). Because 
at that time a role for OCT2  in gentamicin transport was 
not considered, the effect of metformin on the renal uptake 
of gentamicin was not explored. Later on, it was shown that 
gentamicin is an OCT2 substrate as well, and that gentamicin 
uptake in primary cultured proximal tubular cells was suppressed 
by co-incubation with metformin (Gai et  al., 2016). To sort 
out what is the prevalent protective mechanism exerted by 
metformin, experiments with other mitotoxic drugs that are 
not substrates of OCT2 and experiments in isolated mitochondria 
are required. The other protective approach that attracted 
several research groups is promoting the anti-oxidant activity 
of the cell, thereby coping better with the high level of oxidative 
stress subsequent to the mitochondrial injury. There is a plethora 
of in vitro and animal studies showing the nephroprotective 
effect of different types of antioxidant supplementation in DIKI, 
yet the subsequent human studies were not just as much 
practical (Heidari, 2019). Ascorbic acid, a potent reducing 
agent and radical scavenger, was effective against kidney injury 
induced by several drugs causing mitochondrial damage, 
including gentamicin, colistin, and cisplatin (Niki, 1991; May 
et  al., 1995; Antunes et  al., 2000; Sharma and Mongan, 2001; 
Yousef et  al., 2012; Moreira et  al., 2014). In a small clinical 
trial, ascorbic acid failed to protect the kidneys of patients 
taking colistin (Sirijatuphat et al., 2015). Supplementation with 
N-acetylcysteine, a sulfhydryl-donor with well-known antioxidant 
properties, hindered the glomerular filtration deterioration in 
rats treated with amphotericin B (Feldman et  al., 2005). 
Conversely, oral N-acetylcysteine administration to patients 
under amphotericin B treatment did not prevent the onset of 
the nephrotoxicity (Karimzadeh et  al., 2014).
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CONCLUSIONS
Mitochondrial injury is a common event in drug-induced 
toxicity. The renal liability of some drugs is likely to be  the 
result of the high mitochondrial density in the cytoplasm of 
tubular cells coupled to the vast array of drug transporters 
highly expressed on the basolateral and brush border membrane 
of proximal tubular cells. To improve the safety and thus the 
therapeutic window of these drugs, the first important step 
is to study in detail their cellular and molecular pharmacology. 
It is of particular importance to comprehensively characterize 
the cellular and subcellular transport and the molecular target(s) 
of nephrotoxic drugs. Additionally, it is essential to optimize, 
in humans, dose and treatment schedule of the antioxidant 
supplementation approaches that have been successfully tested 
in animals to fill in the shortest time possible, the shortcoming 
of safe nephroprotective strategies. Information resulting from 
such targeted studies could be  exploited to design 
pharmacological strategies, which uncouple the uptake of the 
drug from its toxic effect at the expense of the mitochondria 
by selective inhibition of the drug uptake into the proximal 
tubular cells and/or by reducing the oxidative stress burden 
derived from the mitochondrial damage.
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